Corporate Profile
To become a world leader in the development of targeted antiviral therapies for chronic hepatitis B (CHB) and COVID-19 and to leverage our expertise in liver diseases to create optimized therapeutics for NASH.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
News Releases
Nov 16, 2020
Nov 13, 2020
Events
Dec 1 - Dec 3, 2020
Nov 19, 2020 at 10:50 AM EST